Evidence map›Paper›PMID 37443005›Full record

ArticleBMC biology2023

Increased prime edit rates in KCNQ2 and SCN1A via single nicking all-in-one plasmids.

N Dirkx, Wout J Weuring, E De Vriendt, N Smal, J van de Vondervoort, Ruben van 't Slot, M Koetsier, N Zonnekein, Tim De Pooter, S Weckhuysen and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Emerging Perspectives on Prime Editor Delivery to the Brain.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

N Dirkx *Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium. nina.dirkx@uantwerpen.vib.be.
Wout J Weuring *Department of Genetics, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands. woutweuring2@gmail.com.ORCID 0000-0002-7439-5653
E De VriendtApplied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
N SmalApplied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
J van de VondervoortDepartment of Genetics, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.
Ruben van 't SlotDepartment of Genetics, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.
M KoetsierDepartment of Genetics, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.
N ZonnekeinApplied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Tim De PooterDepartment of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
S WeckhuysenApplied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
B P C KoelemanDepartment of Genetics, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.
University of Antwerp · BEUniversity Medical Center Utrecht · NLUtrecht University · NLVIB-UAntwerp Center for Molecular Neurology · BE

Funding

European Joint Programme on Rare Disease JTC 2020 TreatKCNQFWO-FKM 1861419NFWO-FKM G041821NFWO-SB 1S59221NVrienden WKZ 1616091 (MING)
6 · The paper itself

Abstract

backgroundPrime editing (PE) is the most recent gene editing technology able to introduce targeted alterations to the genome, including single base pair changes, small insertions, and deletions. Several improvements to the PE machinery have been made in the past few years, and these have been tested in a range of model systems including immortalized cell lines, stem cells, and animal models. While double nicking RNA (dncRNA) PE systems PE3 and PE5 currently show the highest editing rates, they come with reduced accuracy as undesired indels or SNVs arise at edited loci. Here, we aimed to improve single ncRNA (sncRNA) systems PE2 and PE4max by generating novel all-in-one (pAIO) plasmids driven by an EF-1α promoter, which is especially suitable for human-induced pluripotent stem cell (hiPSC) models.

resultspAIO-EF1α-PE2 and pAIO-EF1α-PE4max were used to edit the voltage gated potassium channel gene KCNQ2 and voltage gated sodium channel gene SCN1A. Two clinically relevant mutations were corrected using pAIO-EF1α-PE2 including the homozygous truncating SCN1A R612* variant in HEK293T cells and the heterozygous gain-of-function KCNQ2 R201C variant in patient-derived hiPSC. We show that sncRNA PE yielded detectable editing rates in hiPSC ranging between 6.4% and 9.8%, which was further increased to 41% after a GFP-based fluorescence-activated cell sorting (FACS) cell sorting step. Furthermore, we show that selecting the high GFP expressing population improved editing efficiencies up to 3.2-fold compared to the low GFP expressing population, demonstrating that not only delivery but also the number of copies of the PE enzyme and/or pegRNA per cell are important for efficient editing. Edit rates were not improved when an additional silent protospacer-adjacent motif (PAM)-removing alteration was introduced in hiPSC at the target locus. Finally, there were no genome-wide off-target effects using pAIO-EF1α-PE2 and no off-target editing activity near the edit locus highlighting the accuracy of snc prime editors.

conclusionTaken together, our study shows an improved efficacy of EF-1α driven sncRNA pAIO-PE plasmids in hiPSC reaching high editing rates, especially after FACS sorting. Optimizing these sncRNA PE systems is of high value when considering future therapeutic in vivo use, where accuracy will be extremely important.

Indexed as

CRISPR-Cas SystemsRNA, Small UntranslatedAnimalsHEK293 CellsHumansKCNQ2 Potassium ChannelNAV1.1 Voltage-Gated Sodium ChannelPeptide Elongation Factor 1PlasmidsKCNQ2 Potassium ChannelKCNQ2 protein, humanNAV1.1 Voltage-Gated Sodium ChannelPeptide Elongation Factor 1RNA, Small UntranslatedSCN1A protein, humanCRISPRDevelopmental and epileptic encephalopathyEF-1alfaEIEEGene editingHuman-induced pluripotent stem cellsKCNQ2Monogenic diseasesPrime editingSCN1A

Identifiers

PMID37443005
PMCPMC10347817
OpenAlexW4384155014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.